

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/633,630	
			Filing Date	August 5, 2003	
			First Named Inventor	Jörg Kaufmann	
			Art Unit	1635	
			Examiner Name	Kimberly Chong	
Sheet	1	of	9	Attorney Docket Number	ST-101XT

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US- 60/352,873	02-01-2002	Damha, M. J. <i>et al.</i>	All
	U2	US-60/358,580	02-20-2002	Beigelman, L. <i>et al.</i>	All
	U3	US-60/363,124	03-11-2002	Beigelman, L. <i>et al.</i>	All
	U4	US-60/386,782	06-06-2002	Beigelman, L. <i>et al.</i>	All
	U5	US-2003/0135033 A1	07-17-2003	Klippel-Giese, A. <i>et al.</i>	All
	U6	US-2004/0106569 A1	06-03-2004	Klippel-Giese, A. <i>et al.</i>	All
	U7	US-2004/0180351 A1	09-16-2004	Giese, K., <i>et al.</i>	All
	U8	US-2005/0043263 A1	02-24-2005	Giese, K., <i>et al.</i>	All
	U9	US-2006/0217329 A1	09-28-2006	Feinstein, E.	All
	U10	US-2006/0240022 A1	10-26-2006	Klippel-Giese, A. <i>et al.</i>	All
	U11	US- 4,217,294	08-12-1980	Petty, H.E.	All
	U12	US- 5,466,786	11-14-1995	Buhr, C. A. <i>et al.</i>	All
	U13	US- 5,589,389	12-31-1996	Pages, E. <i>et al.</i>	All
	U14	US- 5,670,633	09-23-1997	Cook, P. D. <i>et al.</i>	All
	U15	US- 5,792,847	08-11-1998	Buhr, C.A. <i>et al.</i>	All
	U16	US- 5,872,232	02-16-1999	Cook, P.D. <i>et al.</i>	All
	U17	US- 5,898,031	04-27-1999	Crooke, S.T.	All
	U18	US- 5,914,396	06-22-1999	Cook, P.D. <i>et al.</i>	All
	U19	US- 6,005,087	12-21-1999	Cook, P.D. <i>et al.</i>	All
	U20	US- 6,129,912	10-10-2000	Hortin, G. L. <i>et al.</i>	All
	U21	US- 6,153,737	11-28-2000	Manoharan, M. <i>et al.</i>	All
	U22	US- 6,284,267	09-04-2001	Aneja, R.	All
	U23	US- 6,476,205	11-05-2002	Buhr, C. A. <i>et al.</i>	All

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/633,630	
			Filing Date	August 5, 2003	
			First Named Inventor	Jörg Kaufmann	
			Art Unit	1635	
			Examiner Name	Kimberly Chong	
Sheet	2	of	9	Attorney Docket Number	ST-101XT

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U24	US- 6,506,559	01-14-2003	Fire, A. <i>et al.</i>	All
	U25	US- 6,531,584	03-11-2003	Cook, P.D. <i>et al.</i>	All
	U26	US- 6,812,204	11-02-2004	McHale, A. P. <i>et al.</i>	All
	U27	US- 7,056,704	06-06-2006	Tuschl, T. <i>et al.</i>	All
	U28	US- 7,074,863	07-11-2006	Ekholm, P. <i>et al.</i>	All
	U29	US- 7,078,196	07-18-2006	Tuschl, T. <i>et al.</i>	All
	U30	US- 7,138,517	11-21-2006	Cook, P.D. <i>et al.</i>	All
	U31	US- 7,148,342	12-12-2006	Tolentino, M. J. <i>et al.</i>	All
	U32	US- 7,196,184	03-27-2007	Heidenreich, O. <i>et al.</i>	All
	U33	US- 2003/0027783	02-06-2003	Zernicka-Goetz, M. <i>et al.</i>	All
	U34	US- 2003/0108923	06-12-2003	Tuschl, T. <i>et al.</i>	All
	U35	US- 2004/0053875	03-18-2004	Kreutzer, R. <i>et al.</i>	All
	U36	US- 2004/0072779	04-15-2004	Kreutzer, R. <i>et al.</i>	All
	U37	US- 2004/0102408	05-27-2004	Kreutzer, R. <i>et al.</i>	All
	U38	US- 2004/0180351	09-16-2004	Giese, K. <i>et al.</i>	All
	U39	US- 2005/0100907	05-12-2005	Kreutzer, R. <i>et al.</i>	All
	U40	US- 2006/0094678	05-04-2006	Vornlocher, H. <i>et al.</i>	All
	U41	US- 2006/0142226	06-29-2006	Polisky, B. <i>et al.</i>	All
	U42	US- 2007/0027097	02-01-2007	Lewis, D. L.	All
	U43	US-2007/0093445	04-26-2007	Tuschl, T. <i>et al.</i>	All
	U44	US- 2007/0135372	06-14-2007	MacLachlan, I. <i>et al.</i>	All
	U45	US- 2007/0265220	11-15-2007	Rossi, J. J. <i>et al.</i>	All
	U46	US- 2004/0175703	09-09-2004	Kreutzer, R. <i>et al.</i>	All
	U47	US-7,348,314	03-25-2008	John, M. <i>et al.</i>	All

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/633,630
				Filing Date	August 5, 2003
				First Named Inventor	Jörg Kaufmann
				Art Unit	1635
				Examiner Name	Kimberly Chong
Sheet	3	of	9	Attorney Docket Number	ST-101XT

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	EP- 02018572.4	08-14-2002	Atugen AG	All	
	F2	WO 03/064441 A2	08-07-2003	McGill University	All	
	F3	EP- 1 214 945 B1	06-08-2003	Ainylam Europe AG	All	
	F4	EP- 1 230 375 B1	07-06-2005	Cancer Research Technology Ltd	All	
	F5	EP- 1 407 044 B1	09-19-2007	Max-Planck- Gesellschaft	All	
	F6	EP- 1 798 285 A1	06-20-2007	Ainylam Europe AG	All	
	F7	EP- 1 550 719 A1	07-06-2005	Ainylam Europe AG	All	
	F8	EP- 1 527 176 B1	01-03-2007	Atugen AG	All	
	F9	GB- 2417727 B	01-16-2008	Ainylam Europe AG	All	
	F10	WO 2007/048244 A2	05-03-2007	Topigen Pharmaceuticals, Inc.	All	
	F11	WO 01/75164 A2	10-11-2001	Whitehead Institute for Biomedical Research <i>et al.</i>	All	
	F12	WO 02/055693 A2	07-18-2002	Ribopharma AG	Abstract Only All	
	F13	WO 2004/015107 A3	02-19-2004	Atugen AG	All	
	F14	WO 2004/019973 A1	03-11-2004	Atugen AG	All	
	F15	WO 2004/035615 A2	04-29-2004	Atugen AG	All	
	F16	WO 2005/000320 A2	01-06-2005	Atugen AG	All	
	F17	WO 2005/105152	11-10-2005	Atugen AG	All	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/633,630
				Filing Date	August 5, 2003
				First Named Inventor	Jörg Kaufmann
				Art Unit	1635
				Examiner Name	Kimberly Chong
Sheet	4	of	9	Attorney Docket Number	ST-101XT

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	16
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F18	WO 2006/023544 A2	03-02-2006	Quark Biotech, Inc. <i>et al.</i>	All	
	F19	WO 2006/069782 A2	07-06-2006	Atugen AG	All	
	F20	WO 2007/084684 A2	07-26-2007	Quark Biotech, Inc. <i>et al.</i>		
	F21					
	F22					
	F23					
	F24					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/633,630	
			Filing Date	August 5, 2003	
			First Named Inventor	Jörg Kaufmann	
			Group Art Unit	1635	
			Examiner Name	Kimberly Chong	
			Attorney Docket Number	ST-101XT	
Sheet	5	of	9		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	AMARZGUIQUI, M. <i>et al.</i> "Tolerance for mutations and chemical modifications in a siRNA", <i>Nucleic Acids Research</i> , 2003, pp. 589-595, Vol. 31, No. 2.	
	R2	BERTRAND, J. <i>et al.</i> "Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo", <i>Biochemical and Biophysical Research Communications</i> , 2002, pp. 1000-1004, Vol. 296.	
	R3	BILLY, E. <i>et al.</i> "Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines", <i>PNAS</i> , December 4, 2001, pp. 14428-14433, Vol. 98, No. 25.	
	R4	BOUTLA, A. <i>et al.</i> "Short 5'-phosphorylated double-stranded RNAs induce RNA interference in <i>Drosophila</i> ", <i>Current Biology</i> , November 13, 2001, pp. 1776-1780, Vol. 11.	
	R5	BRAASCH, D.A. <i>et al.</i> "RNA Interference in Mammalian Cells by Chemically-Modified RNA", <i>Biochemistry</i> , 2003, pp. 7967-7975, Vol. 42.	
	R6	BROWN, K. M. <i>et al.</i> "Target accessibility dictates the potency of human RISC", <i>Nature Structural & Molecular Biology</i> , May 2005, pp. 469-470, Vol. 12, No. 5.	
	R7	CHIU, Y. <i>et al.</i> "RNAi in Human Cells: Basic Structural and Functional Features of Small Interfering RNA", <i>Molecular Cell</i> , September 2002, pp. 549-561, Vol. 10.	
	R8	CLAYTON, J. "The Silent Treatment", <i>Nature</i> , September 30, 2004, pp.599-605, Vol. 431.	
	R9	CLEMENS, M. J. "PKR- A Protein Kinase Regulated by Double-stranded RNA", <i>Int. J. Biochem. Cell Biol.</i> , 1997, pp. 945-949, Vol. 29, No. 7.	
	R10	CLEMENS, J.C. <i>et al.</i> "Use of double-stranded RNA interference in <i>Drosophila</i> cell lines to dissect signal transduction pathways", <i>PNAS</i> , June 6, 2000, pp. 6499-6503, Vol. 97, No. 12.	
	R11	CROOKE, R. M. <i>et al.</i> "Metabolism of Antisense Oligonucleotides in Rat Liver Homogenates", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 2000, pp. 140-149, Vol. 292.	
	R12	CZAUDEA, F. <i>et al.</i> "Functional Studies of the PI(3)-kinase signaling pathway employing synthetic and expressed siRNA", <i>Nucleic Acids Research</i> , 2003, pp. 670-682, Vol. 31, No. 2.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			<i>Complete if Known</i>		
			Application Number	10/633,630	
			Filing Date	August 5, 2003	
			First Named Inventor	Jörg Kaufmann	
			Group Art Unit	1635	
			Examiner Name	Kimberly Chong	
Sheet	6	of	9	Attorney Docket Number	ST-101XT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R13	DORSETT, Y. <i>et al.</i> "siRNAs: Applications in Functional Genomics and Potential as Therapeutics", <i>Drug Discovery</i> , April 2004, pp. 318-329, Vol. 3.	
	R14	GARY, D. J. <i>et al.</i> "Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery", <i>Journal of Controlled Release</i> , 2007, pp. 64-73, Vol. 121.	
	R15	HALL, I. M. <i>et al.</i> "Establishment and Maintenance of a Heterochromatin Domain", <i>Science</i> , September 27, 2002, pp. 2232-2237, Vol. 297.	
	R16	HAMMOND, S. M. <i>et al.</i> "Argonaute2, a Link Between Genetic and Biochemical Analyses of RNAi", <i>Science</i> , August 10, 2001, pp. 1146-1150, Vol. 293.	
	R17	HAMMOND, S.M. <i>et al.</i> "An RNA-directed nuclease mediates post-transcriptional gene silencing in <i>Drosophila</i> cells", <i>Nature</i> , March 16, 2000, pp. 293-296, Vol. 404.	
	R18	HANNON, G. J. "RNA interference", <i>Nature</i> , July 11, 2002, pp. 244-251, Vol. 418.	
	R19	HARBORTH, J. <i>et al.</i> "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing", <i>Antisense and Nucleic Acid Drug Development</i> , 2003, pp. 83-105, Vol. 13.	
	R20	HOERTER, J. A. <i>et al.</i> "Chemical Modification Resolves the Asymmetry of siRNA Strand Degradation in Human Blood Serum", <i>RNA</i> , 2007, pp. 1-7, Vol. 13.	
	R21	HU, X. <i>et al.</i> "Relative gene-silencing efficiencies of small interfering RNAs targeting sense and antisense transcripts from the same genetic locus", <i>Nucleic Acids Research</i> , 2004, pp-4609-4617, Vol. 32, No. 15.	
	R22	INOUE, A. <i>et al.</i> "Molecular Design and Delivery of siRNA", <i>Journal of Drug Targeting</i> , 2006, pp. 448-455, Vol. 14, No. 7.	
	R23	JACKSON, A. L. <i>et al.</i> "Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing", <i>RNA</i> , 2006, pp. 1197-1205, Vol. 12.	
	R24	KLIPPEL, A. <i>et al.</i> "The Interaction of Small Domains between the Subunits of Phosphatidylinositol 3-Kinase Determines Enzyme Activity", <i>Molecular and Cellular Biology</i> , April 1994, pp. 2675-2685, Vol. 14, No. 4.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/633,630	
			Filing Date	August 5, 2003	
			First Named Inventor	Jörg Kaufmann	
			Group Art Unit	1635	
			Examiner Name	Kimberly Chong	
Sheet	7	of	9	Attorney Docket Number	ST-101XT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R25	KOLLER, E. <i>et al.</i> "Competition for RISC binding predicts <i>in vitro</i> potency of siRNA", <i>Nucleic Acids Research</i> , 2006, pp. 4467-4476, Vol. 34, No. 16.	
	R26	LAYZER, J. M. <i>et al.</i> "In vivo activity of nuclease-resistant siRNAs", <i>RNA</i> , 2004, pp. 766-771, Vol. 10.	
	R27	LEENDERS, F. <i>et al.</i> "PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase", <i>The EMBO Journal</i> , 2004, pp. 3303-3313, Vol. 23, No. 16.	
	R28	LIMA, W. F. <i>et al.</i> "Structural Requirements at the Catalytic Site of the Heteroduplex Substrate for Human RNase H1 Catalysis", <i>The Journal of Biological Chemistry</i> , August 27, 2004, pp. 36317-36326, Vol. 279, No. 35.	
	R29	LUBINI, P. <i>et al.</i> "Stabilizing effects of the RNA 2'-substituent: crystal structure of an oligodeoxynucleotide duplex containing 2'-O- methylated adenosines", <i>Chemistry & Biology</i> , September 1994, pp. 39-45, Vol. 1.	
	R30	MANOHARAN, M. "RNA interference and chemically modified small interfering RNAs", <i>Current Opinion in Chemical Biology</i> , 2004, pp. 570-579, Vol. 8.	
	R31	MARTINEZ, J. <i>et al.</i> "RISC is a 5' phosphomonoester-producing RNA endonuclease", <i>Genes & Development</i> , 2004, pp. 975-980, Vol. 18.	
	R32	MARTINEZ, J. <i>et al.</i> "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi", <i>Cell</i> , September 6, 2002, pp. 563-574, Vol. 110.	
	R33	MORRISSEY, D. V. <i>et al.</i> "Chemical Modification of Synthetic siRNA", <i>Pharmaceutical Discovery</i> , May 13, 2005.	
	R34	OLIVEIRA, S. <i>et al.</i> "Targeted Delivery of siRNA", <i>Journal of Biomedicine and Biotechnology</i> , 2006, pp. 1-9, Vol. 2006.	
	R35	PADDISON, P. J. <i>et al.</i> "Stable suppression of gene expression by RNAi in mammalian cells", <i>PNAS</i> , February 5, 2002, pp. 1443-1448, Vol. 99, No. 3.	
	R36	PANCOSKA, P. <i>et al.</i> "Efficient RNA interference depends on global context of the target sequence: quantitative analysis of silencing efficiency using Eulerian graph representation of siRNA", <i>Nucleic Acids Research</i> , 2004, pp. 1469-1479, Vol. 32, No. 4.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/633,630	
			Filing Date	August 5, 2003	
			First Named Inventor	Jörg Kaufmann	
			Group Art Unit	1635	
			Examiner Name	Kimberly Chong	
Sheet	8	of	9	Attorney Docket Number	ST-101XT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R37	PARRISH, S. <i>et al.</i> "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference", <i>Molecular Cell</i> , November 2000, pp. 1077-1087, Vol. 6.	
	R38	PATEL, D. J. <i>et al.</i> "Structural Biology of RNA Silencing and Its Functional Implications", <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2006, pp. 81-93, Vol. LXXI.	
	R39	PEEK, A. S. <i>et al.</i> "Design of Active Small Interfering RNAs", <i>Current Opinion in Molecular Therapeutics</i> , 2007, pp. 110-118, Vol. 9, No. 2.	
	R40	PEI, Y. <i>et al.</i> "On the Art of Identifying Effective and Specific siRNAs", <i>Nature Methods</i> , September 2006, pp. 670-676, Vol. 3, No. 9.	
	R41	POTERA, C. "Antisense- down, but not out", <i>Nature Biotechnology</i> , May 2007, pp. 497-499, Vol. 25, No. 5.	
	R42	RANA, T. M. "Illuminating the silence: understanding the structure and function of small RNAs", <i>Molecular Cell Biology</i> , January 2007, pp. 23-36, Vol. 8.	
	R43	RAND, T. A. <i>et al.</i> "Argonaute2 Cleaves the Anti-Guide Strand of siRNA during RISC Activation", <i>Cell</i> , November 18, 2005, pp. 621-629, Vol. 123.	
	R44	ROSSI, J. J. "A Cholesterol connection in RNAi", <i>Nature</i> , November 11, 2004, pp. 155-156, Vol. 432.	
	R45	SANTEL, A. "Get the balance right: Mitofusins roles in health and disease", <i>Biochimica et Biophysica Acta</i> , 2006, pp. 490-499, Vol. 1763.	
	R46	SANTEL, A. <i>et al.</i> "RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy", <i>Gene Therapy</i> , 2006, pp. 1360-1370, Vol. 13.	
	R47	SANTEL, A. <i>et al.</i> "A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium", <i>Gene Therapy</i> , 2006, pp. 1222-1234, Vol. 13.	
	R48	SCHERER, L. J. <i>et al.</i> "Approaches for the sequence-specific knockdown of mRNA", <i>Nature Biotechnology</i> , December 2003, pp. 1457-1465, Vol. 21, No. 12.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/633,630	
			Filing Date	August 5, 2003	
			First Named Inventor	Jörg Kaufmann	
			Group Art Unit	1635	
			Examiner Name	Kimberly Chong	
Sheet	9	of	9	Attorney Docket Number	ST-101XT

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	R49	SCHWARZER, R. <i>et al.</i> "TRB3 is a PI 3-kinase dependent indicator for nutrient starvation", <i>Cellular Signalling</i> , 2006, pp. 899-909, Vol. 18.		
	R50	SNOVE, O. <i>et al.</i> "Chemical Modifications Rescue Off-Target Effects of RNAi", <i>ACS Chemical Biology</i> , 2006, pp. 274-276, Vol. 1, No. 5.		
	R51	TURNER, J. J. <i>et al.</i> "MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNase A-like activity", <i>Molecular BioSystems</i> , 2007, pp. 43-50, Vol. 3.		
	R52	TUSCHL, T. "Expanding small RNA interference", <i>Nature Biotechnology</i> , May 2002, pp. 446-448, Vol. 20.		
	R53	TUSCHL, T. <i>et al.</i> "Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy", <i>Molecular Interventions</i> , June 2002, pp. 158-167, Vol. 2, Issue 3.		
	R54	VOLPE, T. A. <i>et al.</i> "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi", <i>Science</i> , September 13, 2002, pp. 1833-1837, Vol. 297.		
	R55	WILSON, C. <i>et al.</i> "Building oligonucleotide therapeutics using non-natural chemistries", <i>Current Opinion in Chemical Biology</i> , 2006, pp. 607-614, Vol. 10.		
	R56	Delivery Note, 2 pages, December 20, 2001.		
	R57			
	R58			
	R59			
	R60			

Examiner Signature	/Kimberly Chong/	Date Considered	05/22/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.